Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

被引：22

作者：

Connelly, Kim A. ^{[1
,2
]}

Bhatt, Deepak L. ^{[3
]}

Verma, Subodh ^{[4
,5
,6
,7
]}

机构：

[1] Univ Toronto, Div Cardiol, Keenan Res Ctr Biomed Sci, St Michaels Hosp,Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Dept Med, Toronto, ON, Canada

[3] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA USA

[4] Univ Toronto, Div Cardiac Surg, Keenan Res Ctr Biomed Sci, St Michaels Hosp,Dept Surg, Toronto, ON, Canada

[5] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Dept Surg, Toronto, ON, Canada

[6] Univ Toronto, Div Cardiac Surg, Keenan Res Ctr Biomed Sci, St Michaels Hosp,Dept Pharmacol & Toxicol, Toronto, ON, Canada

[7] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Dept Pharmacol & Toxicol, Toronto, ON, Canada

来源：

CELL METABOLISM | 2018年 / 28卷 / 06期

基金：

加拿大健康研究院;

关键词：

CARDIOVASCULAR OUTCOMES; HEART-FAILURE;

D O I：

10.1016/j.cmet.2018.11.010

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Heart failure and renal disease remain significant complications in people with type 2 diabetes (T2D). Recent outcome studies with sodium-glucose cotransporter-2 (SGLT2) inhibitors have provided increasing insights, with the latest reporting trial DECLARE-TIMI 58 (Wiviott et al., 2018), pointing toward a role for these agents in the primary prevention of cardio-renal complications in T2D.

引用

页码：813 / 815

页数：4

共 10 条

[1]

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors [J].

Butler, Javed ;

Hamo, Carine E. ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Bernstein, Richard A. ;

Brueckmann, Martina ;

Cheung, Alfred K. ;

George, Jyothis T. ;

Green, Jennifer B. ;

Januzzi, James L. ;

Kaul, Sanjay ;

Lam, Carolyn S. P. ;

Lip, Gregory Y. H. ;

Marx, Nikolaus ;

McCullough, Peter A. ;

Mehta, Cyrus R. ;

Ponikowski, Piotr ;

Rosenstock, Julio ;

Sattar, Naveed ;

Salsali, Afshin ;

Scirica, Benjamin M. ;

Shah, Sanjiv J. ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Wanner, Christoph ;

Woerle, Hans-Juergan ;

Zannad, Faiez ;

Anker, Stefan D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) :1390-1400

[2]

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology [J].

Maack, Christoph ;

Lehrke, Michael ;

Backs, Johannes ;

Heinzel, Frank R. ;

Hulot, Jean-Sebastien ;

Marx, Nikolaus ;

Paulus, Walter J. ;

Rossignol, Patrick ;

Taegtmeyer, Heinrich ;

Bauersachs, Johann ;

Bayes-Genis, Antoni ;

Brutsaert, Dirk ;

Bugger, Heiko ;

Clarke, Kieran ;

Cosentino, Francesco ;

De Keulenaer, Gilles ;

Dei Cas, Alessandra ;

Gonzalez, Arantxa ;

Huelsmann, Martin ;

Iaccarino, Guido ;

Lunde, Ida Gjervold ;

Lyon, Alexander R. ;

Pollesello, Piero ;

Rena, Graham ;

Riksen, Niels P. ;

Rosano, Giuseppe ;

Staels, Bart ;

van Laake, Linda W. ;

Wanner, Christoph ;

Farmakis, Dimitrios ;

Filippatos, Gerasimos ;

Ruschitzka, Frank ;

Seferovic, Petar ;

de Boer, Rudolf A. ;

Heymans, Stephane .

EUROPEAN HEART JOURNAL, 2018, 39 (48) :4243-+

[3]

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [J].

Marso, Steven P. ;

Daniels, Gilbert H. ;

Brown-Frandsen, Kirstine ;

Kristensen, Peter ;

Mann, Johannes F. E. ;

Nauck, Michael A. ;

Nissen, Steven E. ;

Pocock, Stuart ;

Poulter, Neil R. ;

Ravn, Lasse S. ;

Steinberg, William M. ;

Stockner, Mette ;

Zinman, Bernard ;

Bergenstal, Richard M. ;

Buse, John B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :311-322

[4]

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored [J].

McMurray, John J. V. ;

Gerstein, Hertzel C. ;

Holman, Rury R. ;

Pfeffer, Marc A. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (10) :843-851

[5]

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes [J].

Rawshani, Aidin ;

Rawshani, Araz ;

Franzen, Stefan ;

Eliasson, Bjorn ;

Svensson, Ann-Marie ;

Miftaraj, Mervete ;

McGuire, Darren K. ;

Sattar, Naveed ;

Rosengren, Annika ;

Gudbjornsdottir, Soffia .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (15) :1407-1418

[6]

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk Observations From the SAVOR-TIMI 53 Trial [J].

Scirica, Benjamin M. ;

Mosenzon, Ofri ;

Bhatt, Deepak L. ;

Udell, Jacob A. ;

Steg, Ph Gabriel ;

McGuire, Darren K. ;

Im, KyungAh ;

Kanevsky, Estella ;

Stahre, Christina ;

Sjostrand, Mikaela ;

Raz, Itamar ;

Braunwald, Eugene .

JAMA CARDIOLOGY, 2018, 3 (02) :155-163

[7]

Pump, pipes, and filter: do SGLT2 inhibitors cover it all? [J].

Verma, Subodh ;

Juni, Peter ;

Mazer, C. David .

LANCET, 2019, 393 (10166) :3-5

[8]

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review [J].

Verma, Subodh ;

McMurray, John J. V. .

DIABETOLOGIA, 2018, 61 (10) :2108-2117

[9]

Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]

[10]

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Zelniker, Thomas A. ;

Wiviott, Stephen D. ;

Raz, Itamar ;

Im, Kyungah ;

Goodrich, Erica L. ;

Bonaca, Marc P. ;

Mosenzon, Ofri ;

Kato, Eri T. ;

Cahn, Avivit ;

Furtado, Remo H. M. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Sabatine, Marc S. .

LANCET, 2019, 393 (10166) :31-39

← 1 →